Compugen Ltd. (CGEN)
CGEN Stock Price Chart
Explore Compugen Ltd. interactive price chart. Choose custom timeframes to analyze CGEN price movements and trends.
CGEN Company Profile
Discover essential business fundamentals and corporate details for Compugen Ltd. (CGEN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Aug 2000
Employees
74.00
Website
https://cgen.comCEO
Anat Cohen-Dayag
Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
CGEN Financial Timeline
Browse a chronological timeline of Compugen Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 18 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.07.
Earnings released on 6 Aug 2025
EPS came in at -$0.08 falling short of the estimated -$0.07 by -14.29%, while revenue for the quarter reached $1.26M , missing expectations by -14.45%.
Earnings released on 19 May 2025
EPS came in at -$0.08 falling short of the estimated -$0.06 by -33.33%, while revenue for the quarter reached $2.28M , missing expectations by -38.34%.
Earnings released on 4 Mar 2025
EPS came in at -$0.07 falling short of the estimated $0.07 by -200.00%, while revenue for the quarter reached $1.47M , missing expectations by -70.58%.
Earnings released on 12 Nov 2024
EPS came in at $0.01 falling short of the estimated $0.06 by -83.33%, while revenue for the quarter reached $17.13M , missing expectations by -4.08%.
Earnings released on 6 Aug 2024
EPS came in at -$0.02 surpassing the estimated -$0.08 by +75.00%, while revenue for the quarter reached $6.70M , beating expectations by +169.16%.
Earnings released on 20 May 2024
EPS came in at -$0.08 surpassing the estimated -$0.10 by +20.00%, while revenue for the quarter reached $2.56M , missing expectations by -58.79%.
Earnings released on 5 Mar 2024
EPS came in at $0.11 falling short of the estimated $0.23 by -52.17%, while revenue for the quarter reached $33.46M , beating expectations by +67.30%.
Earnings released on 7 Nov 2023
EPS came in at -$0.11 falling short of the estimated -$0.09 by -22.22%, while revenue for the quarter reached $8.00M , missing expectations by -52.52%.
Earnings released on 7 Aug 2023
EPS came in at -$0.11 surpassing the estimated -$0.13 by +15.38%.
Earnings released on 15 May 2023
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%.
Earnings released on 27 Feb 2023
EPS came in at -$0.04 surpassing the estimated -$0.14 by +71.43%, while revenue for the quarter reached $7.50M .
Earnings released on 14 Nov 2022
EPS came in at -$0.14 falling short of the estimated -$0.13 by -7.69%.
Earnings released on 4 Aug 2022
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%.
Earnings released on 16 May 2022
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%.
Earnings released on 24 Feb 2022
EPS came in at -$0.10 surpassing the estimated -$0.15 by +33.33%, while revenue for the quarter reached -$5.15M , missing expectations by -615.10%.
Earnings released on 12 Nov 2021
EPS came in at -$0.07 surpassing the estimated -$0.13 by +46.15%, while revenue for the quarter reached $6.00M , missing expectations by -21.57%.
Earnings released on 28 Jul 2021
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%.
Earnings released on 13 May 2021
EPS came in at -$0.12 matching the estimated -$0.12.
Earnings released on 25 Feb 2021
EPS came in at -$0.10 matching the estimated -$0.10, while revenue for the quarter reached $2.00M , meeting expectations.
Earnings released on 5 Nov 2020
EPS came in at -$0.09 matching the estimated -$0.09.
CGEN Stock Performance
Access detailed CGEN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.